‘Placing their cash the place their mouth is’: This is what three analysts should say about Coinbase’s choice so as to add $500 million of crypto to its stability sheet | Foreign money Information | Monetary and Enterprise Information

Coinbase Co-Founder and CEO Brian Armstrong

Coin base announced on Thursday that it was Add $ 500 million in cryptocurrency to its balance sheet while at the same time 10% of its quarterly net income is allocated to a portfolio of crypto assets. Insider gathered insights from three Coinbase analysts to help understand the move.

“I like that they put their money where their lips are,” said Mizuho analyst Dan Dolev.

He told Insiders that Coinbase is still heavily fiat money for a company with crypto headquarters for its business. This move changes that, although Dolev would like the exchange to go a step further and charge customer transaction fees in crypto rather than dollars.

“That would signal even more commitment to the cryptocurrency,” said Dolev.

Coinbase CFO Alesia Haas admitted that the majority of Coinbase’s financial transactions – like paying sellers and employees or investing company money – on a Friday are “heavily weighted” in fiat blog entry. But she said Coinbase wants to lead by example by enabling the adoption and use of crypto, and that investment is a step towards that goal.

“We believe that more and more companies will keep crypto assets on their balance sheets in the future,” said Haas. “We hope that by incorporating more crypto assets into our own corporate financial practices, we can take another step towards a more open crypto economy.”

Chris Kuiper, a CFRA stock research analyst, reiterated Dolev’s comment that the announcement shows Coinbase’s commitment to the cryptocurrency industry. Kupier maintained his “Buy” rating on Coinbase after it was announced that he was broadly positive on the stock.

However, adding crypto to Coinbase’s balance sheet adds an additional layer of risk as the company’s share price is already tied to the price and trading activity of Bitcoin, Chris Brendler, senior research analyst at DA Davidson, told Insider. The Coinbase share often moves in parallel with the Bitcoin price.

“That won’t necessarily make or destroy the company,” Brendler told Insider. “But it’s certainly a little scary when you put money into one of those commodities that you’re already pretty closely connected with.”

Part of this risk is offset by a cash balance of $ 4 billion that Coinbase is building in anticipation of a “crypto winter” and possible regulatory action, said Kupier.

Brendler added that since Coinbase is so tied to crypto, Coinbase will need to have more cash than other high-growth non-crypto companies in case there is a “crypto winter” or a prolonged period of low crypto prices and activity.

Dwell Nation Leisure, Inc. (NYSE:LYV): Are Analysts Optimistic?

With the business possibly at an important milestone, we thought we should take a closer look Live Nation Entertainment, Inc. (NYSE: LYV) Future prospects. Live Nation Entertainment, Inc. operates as a live entertainment company. With a recent loss of $ 1.7 billion and a loss of $ 1.8 billion over the past twelve months, the $ 20 billion market-cap company added to its loss by moving further from its break-even point. Target distant. With the road to profitability being the theme for Live Nation Entertainment investors, we decided to measure market sentiment. In this article, we look at expectations for the company’s growth and when analysts expect it to be profitable.

Check out our latest analysis for Live Nation Entertainment

According to the 14 industry analysts at Live Nation Entertainment, there is consensus that break-even is close. They anticipate the company will post a final loss in 2021 before posting positive profit of $ 243 million in 2022. Hence, the company is expected to break even in a little over a year. How fast does the company have to grow each year to break even by 2022? Based on the analysts’ estimates, it turns out that they expect the company to grow an average of 58% year-on-year, which signals a high level of analyst confidence. If this rate turns out to be too aggressive, the company can become profitable much later than analysts predict.

NYSE: LYV earnings per share growth June 4, 2021

Since this is a general overview, we won’t go into Live Nation Entertainment’s upcoming projects, but keep in mind that a high rate of growth is generally not uncommon, especially when a company is at a time of investment.

One thing that we want to bring to light with Live Nation Entertainment is that it currently has negative equity on its balance sheet. Accounting policies used to handle losses accumulated over time can cause this. This is because liabilities are carried forward until they are canceled. These losses usually only appear on paper, but can be a warning in other cases.

Next Steps:

There are too many aspects of Live Nation Entertainment to be covered in one short article, but the most important fundamentals for the company are all in one place – Live Nation Entertainment corporate page on Simply Wall St. We’ve also put together a list of key factors to keep in mind:

  1. rating: What is Live Nation Entertainment worth today? Is the future growth potential already factored into the price? The Infographic on intrinsic value in our free research report helps to visualize whether Live Nation Entertainment is currently being mispriced by the market.
  2. Management team: An experienced management team at the top strengthens our confidence in the business – see who sits on the board of Live Nation Entertainment and the background of the CEO.
  3. Other high performing stocks: Are there any other stocks that have a proven track record of offering better prospects? Discover our Free list of these great stocks here.

Funded
When trading Live Nation Entertainment or other investments, use the platform considered by many to be the professional gateway to the world market. Interactive brokers. Get the cheapest * trading in stocks, options, futures, forex, bonds and funds worldwide from a single integrated account.

This article from Simply Wall St is of a general nature. It is not a recommendation to buy or sell stocks and does not take into account your goals or your financial situation. Our goal is to provide you with long-term, focused analysis based on fundamentals. Note that our analysis may not take into account the latest company announcements or quality material, which may be sensitive to the price. Simply Wall St has no position in the stocks mentioned.
* Interactive Brokers rated as the lowest cost broker by StockBrokers.com Annual Online Review 2020

Do you have any feedback on this article? Concerned about the content? Get in touch directly with us. Alternatively, send an email to the editorial team (at) simplywallst.com.

Analysts cheer ‘surprisingly constructive’ AstraZeneca U.S. trial information

A bottle of the AstraZeneca vaccine.

Igor Petyx | KONTROLAB | LightRocket via Getty Images

Health analysts welcomed AstraZenecaThe results of the much-anticipated late-stage US study results for the Covid-19 vaccine.

The study of more than 30,000 participants in the US, Peru, and Chile found the vaccine to be a Overall effectiveness of 79% in preventing symptomatic Covid and 100% effectiveness in preventing serious illness and hospitalization.

Efficacy was consistent across ages and races, with 80% effectiveness in participants 65 and over. Known as AZD1222 and jointly developed with Oxford University, the vaccine was well tolerated and the independent data security watchdog did not find any security concerns related to the vaccine, the company said Monday.

The data exceeded expectations

In a research note, Jefferies health analyst Peter Welford described the data as “surprisingly positive”.

Adam Barker, Health Analyst at Shore Capital, said, “This is arguably the first study for AZD1222 that has shown convincing efficacy in those 65 years and older.”

This is important as there have been questions about its effectiveness in this age group. Previous studies have been hampered by fewer older participants. In this study, 20% of participants were 65 years of age or older and 60% had comorbidities, which placed them at increased risk of developing serious illnesses.

Monday’s trial data confirmed the vaccine’s safety profile. Barker said that having the data from a single study with a single-dose regimen removes the data interpretation complications seen in the past with the AstraZeneca-Oxford vaccine.

Barker added that the lack of evidence of blood clots in the study was also comforting in light of recent concerns. “We are not surprised by these data, however, as the evidence of a link between the vaccine and the blood clots was already quite weak.”

AstraZeneca said it will continue to analyze the data and prepare for the primary analysis to be submitted to the U.S. Food and Drug Administration for emergency approval in the coming weeks. The vaccine has already received conditional marketing or emergency marketing authorization in more than 70 countries on six continents.

Dosing regimen a key issue for the FDA

“I can’t understand why the regulator wouldn’t approve this,” Barker wrote, but warned that the detailed data is pending.

A key question for the FDA will be what dosage regimen it will endorse should it end up using the vaccine in an emergency.

“This study is based on dosing 4 weeks apart, but we know The effectiveness can be higher if you dose with a longer interval (up to 12 weeks) and countries like the UK have successfully used this “longer period between doses” strategy to vaccinate more people quickly, “Barker said.

So the question for the FDA is whether it will recommend giving the two doses four weeks apart – assuming this was tested in the US study – or including data from the UK and other countries suggesting a longer duration .

Welford also noted the sub-optimal dosing regimen used in this study. “The study evaluated the 4-week dosing schedule, but we have evidence that the vaccine works better with longer dosing intervals,” he said.

“The primary analysis of the UK, Brazil and South Africa Phase III clinical trials found 62% efficacy when the vaccine was given 4 to 12 weeks apart, but efficacy increased to 82% when the interval was 12 weeks has been extended. “”

In addition to the dosage, analysts also observe in detail how the vaccine protects against different variants. This is expected to be included in the data packet that will be submitted to the FDA.

When it comes to comparing today’s efficacy data with that of some other vaccine manufacturers, Welford has been warning since the first vaccine readings from Pfizer and ModernCovid-19 variants have become more and more common, so the effectiveness data for the different vaccines cannot be directly compared.

Barker added that the trial results gave the vaccine important validation. “Because of its cost and ease of storage and distribution, AZD1222 was once dubbed the ‘Vaccine for the World’. We think this is a fair label,” he wrote. “Data like this, reported today to be more conclusive about the effectiveness and safety of AZD1222, is certainly cause for celebration.”

AstraZeneca has committed to distribute the vaccine for the duration of the pandemic for no profit. The company’s shares traded 2% higher in London on Monday.

Analysts Simply Made A Main Revision To Their Ten Leisure Group plc (LON:TEG) Income Forecasts

TipRanks

2 penny stocks with strong buy that could generate oversized profits

Well it’s official. Joe Biden is now president and is supported – at least in the short term – by Democratic majorities in both houses of Congress. Wall Street is taking the action of the new administration and is seeing its first steps spike in fiscal stimulus, which is expected to boost consumer spending, weigh on corporate earnings and provide general economic support in the first half of 2021 The situation for Goldman Sachs is investment strategist David Kostin who is optimistic about the near-term outlook for fiscal stimulus. Against this background, Kostin sets the Goldman outlook for this year at a GDP growth of 6.4%. He sees continued high growth in the next year and sets the forecast for 2022 at 4%. These outlook figures are above the previously published 5.9% and 3.7%. To that end, Kostin sees the S&P 500 hit 4,300 by the end of the year, which is a 12% gain over current levels. “Elections have consequences. Democratic control of Washington, DC after January 20th will bring higher budget spending, faster GDP growth, more inflation and higher interest rates than we previously anticipated, ”Kostin noted. As the markets look up, investors look for stocks that are ready for profit. Penny stocks, stocks priced less than $ 5 per share, are a natural place to look for potential winners. Their low price means that even a small increment will result in large percentages. Before investing directly in any penny stock investment, however, Wall Street pros recommend looking at the bigger picture and considering other factors beyond price. Some names that fall into this category really get what you pay for with little long-term growth prospects due to weak fundamentals, recent headwinds, or even large stocks outstanding. With the risk in mind, we used TipRanks’ database to find compelling penny stocks with cheap price tags. The platform led us to two tickers with stock prices below $ 5 and analyst consensus ratings with “strong buy”. Not to mention significant upside potential. AzurRx BioPharma (AZRX) We’re starting a company specializing in gastrointestinal diseases, AzurRx. This company focuses on the development of non-systemic, targeted recombinant therapies for GI diseases. AzurRx has a pipeline of three drug candidates at multiple levels of the development process. The key candidate for the pipeline, MS1819, is currently being investigated for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis. MS1819 is a recombinant lipase derived from a strain of yeast. The drug targets fat molecules in the digestive tract and allows patients to absorb the broken down fats for nutritional value. The drug is currently in phase 2 trials, which are expected to be completed in the first half of this year. As of January 21, the first two patients in the Phase 2b OPTION 2 extension study were given treatment and the Data Monitoring Committee (DMC) “continues to support the program.” In another major development, AzurRx announced earlier this month that it is partnering with First Wave Bio to develop the oral and rectal formulations of niclosamide for the treatment of Immune Checkpoint Inhibitor Associated Colitis (ICI-AC) and COVID-19 -to study gastrointestinal infections caused by the disease. The estimated market for niclosamide for treating COVID-related GI problems exceeds $ 450 million. Based on several potentially significant clinical catalysts plus the $ 0.98 share price, several members of the street believe now is the right time to pull the trigger. Roth Capital’s Jonathan Aschoff is bullish on AzurRx and bases his longer-term projections on the likely success of MS1819. “We base our assessment for AZRX on projected future US sales of MS1819 for the treatment of EPI due to CF and CP. It uses an initial annual price of approximately $ 18,000, a price that is consistent with currently available PERTs. We estimate MS1819 will be commercialized in the US in 2023 and will have sales of $ 272 million in 2030. The commercial success of MS1819 outside the US or the commercial success of the early stage beta-lactamase program would have a positive impact on our assessment, ”said Aschoff. The analyst is also looking forward to the first clinical results of niclosamide in COVID-19 GI infections and ICI-AC, noting: “Niclosamide was approved by the FDA in 1982 for the treatment of tapeworm infections in the intestine and is on the list of major drugs With all of these factors in mind, Aschoff rates AZRX as a buy, and its target price of $ 7 points to a sky-high positive, given the millions of patients who have taken the drug, the safety profile has been largely determined, reducing the risk of development up 608% for the year ahead. (To see Aschoff’s track record, click here) Overall, analyst consensus on AZRX stock is a strong buy; the stock has 4 recent valuations including 3 buys and a single hold. Additionally, the average target price of $ 4 brings the upside potential to 304%. (See AZRX stock analysis on TipRank s) ProQR (PRQR) ProQR is a biotechnology company focused on treatments for congenital progressive blindness. In particular, the company is working on drugs to reverse a group of genetic visual disorders called hereditary retinal diseases. These diseases currently have no effective treatments. The company has a research pipeline of five drug candidates. The two most distant are QR-110 (Sepofarse) and QR-421. Of these two, QR-110 is currently in phase 2/3 studies. This candidate is RNA therapy to correct the m The most common CEP290 gene mutation that causes congenital liver amaurosis 10 (LCA10). This is a serious genetic retinal disease that affects up to 3 in 100,000 children. QR-421 is another RNA therapy that focuses on exon 13 mutations in the USH2A gene. These mutations cause blindness due to retinitis pigmentosa and / or Usher syndrome. QR-421 is in Phase 1/2 studies with the aim of restoring lost vision or preventing it from happening at all. Analyst Jonathan Wolleben covers the stock for JMP, pointing to Sepo arsenic as a key component of his bullish thesis. “We still see the chance of success of sepo arsenic at Illuminate as good for several reasons: 1) Phase 1/2 confirmed the intended registration dose and the dosing interval (6 months); 2) patients had clinically significant and sustained BCVA improvements after 12 months – key primary endpoint; 3) supporting secondary effectiveness measures (FST, mobility); 4) similar reactions in second treated eyes; 5) long-term safety confirms positive risk / benefit; and 6) The illuminated patient population was enriched based on the Phase 1/2 results (baseline vision of> / = hand movement). We assign sepofarsen a POS of 60% and the model LCA10 as an opportunity of ~ 300 million USD for PRQR with maximum penetration, “said Wolleben. In line with his optimistic outlook, Wolleben sets a price target of 20 USD for the share, what a Year of 384% implies up, along with an Outperform (i.e. Buy) rating. (To see Wolleben’s track record, click here.) Overall, PRQR receives a unanimous Strong Buy rating from analyst consensus based on 3 positive stock valuations currently trading $ 4.13, and the average target price of $ 20.67 is slightly more bullish than Wolleben’s, indicating an upward move of 400% for the next 12 months. (See PRQR stock analysis at TipRanks) To get good ideas for To find penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that brings together all of the insights into TipRanks stocks Conclusion: The opinions expressed in this article are solely those of the analysts presented. The content is intended to be used for informational purposes only. He is very impo You must do your own analysis before making any investment.